Gilead Sciences, Inc. (GILD) — Stock Price, Chart & Analysis
Gilead Sciences, Inc. (GILD) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $165.17B. Over the past 52 weeks, GILD has traded between $108.46 and $157.29. Gilead Sciences, Inc. pays a dividend yielding 2.5%. View the live GILD chart, technical opinion, analyst ratings, fundamentals and latest news below.
Gilead Sciences, Inc. (GILD) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $165.17B |
| EPS (TTM) | $-2.70 |
| Dividend yield | 2.5% |
| 52-week high | $157.29 |
| 52-week low | $108.46 |
| Beta | 0.34 |
| Avg. volume | 7.73M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Gilead Sciences, Inc. (GILD)
How much does one share of Gilead Sciences, Inc. cost?
As of the latest update, one share of Gilead Sciences, Inc. (GILD) trades at $100 (+0.00% today).
What is Gilead Sciences, Inc.'s market cap?
Gilead Sciences, Inc. has a market capitalization of approximately $165.17B.
What is Gilead Sciences, Inc.'s earnings per share (EPS)?
Gilead Sciences, Inc.'s trailing twelve-month EPS is $-2.70.
Does Gilead Sciences, Inc. pay a dividend?
Yes — Gilead Sciences, Inc. pays a dividend with a yield of 2.5% ($3.28 per share annually).
What is Gilead Sciences, Inc.'s 52-week trading range?
Over the past year, GILD has traded between $108.46 and $157.29.
What is the analyst price target for Gilead Sciences, Inc.?
The mean analyst price target for Gilead Sciences, Inc. is $157.41. This is informational only and not investment advice.
Latest Gilead Sciences, Inc. (GILD) news
- What Insmed Stock's Premium Is Actually BuyingNews · Aug 7, 2026
- GILD Q2 Earnings Call Raises Outlook on HIV and PrEP StrengthNews · Aug 7, 2026
- KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi PaymentsNews · Aug 6, 2026
- MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim dataNews · Aug 6, 2026
- Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV BeatNews · Aug 5, 2026
- Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ...News · Aug 5, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live GILD dashboard…